Health Trials

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ConditionsAcute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute

About this trial

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS.

The interventions involved in this study are:

* SL-401 * Azacitidine * Venetoclax

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Azacitidine
  • SL-401
  • Venetoclax

Treatment groups

72 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Dana-Farber Cancer Institute

Lead sponsor

Stemline Therapeutics, Inc.

Collaborator

Source ClinicalTrials.gov